Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)

Inclusion Criteria:

• ASA class 1 - 3 for renally impaired patients, ASA class 1-2 for control group

• Age at least 18 years

• Scheduled for general anesthesia without further need for muscle relaxation other thanone single dose of 0.6 mg.kg-1 rocuronium

• Scheduled for surgical procedures in the supine position

• Written informed consent

• Creatinine clearance (CLCR) < 30 mL/min for renally impaired group, CLCR = 80 mL/minfor control group

Exclusion Criteria:

• Known or suspected neuromuscular disorders impairing NMB

• Known or suspected (family) history of malignant hyperthermia

• Known or suspected allergy to narcotics, muscle relaxants or other medication usedduring general anesthesia

• Use of medication known to interfere with NMBA based on the dose and the time ofadministration, such as antibiotics, anticonvulsants and Mg2+

• Pregnancy

• Childbearing potential without using any of the following methods of birth control:condom or diaphragm with spermicide, vasectomized partner ( > 6 months), intrauterinedevice, abstinence

• Breast-feeding

• Prior participation in any trial with Org 25969

• Participation in another clinical trial, not pre-approved by NV Organon, within 30days of entering into trial 19.4.304, or for the UK only: Participation in anotherclinical trial, within 30 days of entering into trial 19.4.304.